SCHEMBL8729784

SCHEMBL8729784

O=C(O)c1cc(=O)[nH]c2ccccc12

nearest known ligand 0.63

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 12/20 0.63
ALDH1A1 P00352 8/20 0.60
HSD17B10 Q99714 3/20 0.60
HPGD P15428 2/20 0.60
TP53 P04637 1/20 0.58
TDP1 Q9NUW8 2/20 0.58
POLB P06746 1/20 0.58
GAA P10253 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
MAPK1 P28482 1/20 0.58
HTT P42858 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
CYP1A2 P05177 1/20 0.56
CYP2C19 P33261 1/20 0.56
TNKS2 Q9H2K2 1/20 0.56
KMT2A Q03164 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30172555 1.00 KDM4E (0.63) KDM4EALDH1A1HSD17B10HPGDTP53
Hydrochloric Acid SCHEMBL26649422 0.98 KDM4E (0.61) KDM4EALDH1A1HSD17B10HPGDTP53
SCHEMBL14177245 0.84 KDM4E (0.59) KDM4EALDH1A1HSD17B10HPGDTP53
SCHEMBL14829872 0.84 KDM4E (0.64) KDM4EALDH1A1HSD17B10HPGDTP53
SCHEMBL31343793 0.84 KDM4E (0.64) KDM4EALDH1A1HSD17B10HPGDTP53
SCHEMBL13451625 0.80 KDM4E (0.67) KDM4EALDH1A1HSD17B10HPGDTP53
SCHEMBL14830559 0.80 KDM4E (0.69) KDM4EALDH1A1HSD17B10HPGDGAA
SCHEMBL2799377 0.80 KDM4E (0.71) KDM4EALDH1A1HSD17B10HPGDTP53
SCHEMBL28982768 0.79 KDM4E (0.63) KDM4EALDH1A1HPGDTDP1POLB
SCHEMBL30020580 0.78 PBRM1 (0.54) KDM4EALDH1A1HSD17B10HPGDTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240374583-A1 USE OF MORPHINAN DERIVATIVES FOR TREATMENT OF OPIOID DELTA RECEPTOR AGONIST-RELATED DISEASE NIPPON CHEMIPHAR CO., LTD (JP) 2024-11-14 US disclosed
US-12109209-B2 Use of morphinan derivatives for treatment of opioid delta receptor agonist-related disease NIPPON CHEMIPHAR CO., LTD. (JP) 2024-10-08 US disclosed
EP-4414037-A2 MORPHINAN DERIVATIVES FOR THE TREATMENT OF OPIOID DELTA RECEPTOR AGONIST-RELATED DISEASES Nippon Chemiphar Co., Ltd. (JP) 2024-08-14 EP disclosed
EP-3513792-B9 MORPHINAN DERIVATIVES FOR THE TREATMENT OF OPIOID DELTA RECEPTOR AGONIST-RELATED DISEASES NIPPON CHEMIPHAR CO (JP) 2024-07-10 EP disclosed
CN-118076593-A 3CLpro protease inhibitors 上海齐鲁制药研究中心有限公司 2024-05-24 CN disclosed
CN-113292559-B Morphinan derivatives 日本化学药品株式会社 2024-04-02 CN disclosed
EP-3513792-B1 MORPHINAN DERIVATIVES FOR THE TREATMENT OF OPIOID DELTA RECEPTOR AGONIST-RELATED DISEASES NIPPON CHEMIPHAR CO (JP) 2024-03-27 EP disclosed
CN-117122598-A Use of morphinan derivatives in the treatment of opioid delta receptor agonist-related diseases 日本化学药品株式会社 2023-11-28 CN disclosed
WO-2023219456-A1 QUINOLINE-BASED HISTONE DEACETYLASE INHIBITORY SUBSTANCES, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME AS ACTIVE INGREDIENT 숙명여자대학교 산학협력단 2023-11-16 WO disclosed
CN-110248658-B Use of morphinan derivatives in the treatment of opioid delta receptor agonist-related diseases 日本化学药品株式会社 2023-10-13 CN disclosed
US-7186841-B2 (2-imidazolyl)quinolin-4-yl aldehydes; immunomodulators, antiproliferative agents; metabolic disorders AMGEN INC. (US) 2007-03-06 US disclosed
US-5849756-A Pharmaceutical composition and method for modulating the immune reaction CERBIOS-PHARMA SA (CH) 1998-12-15 US disclosed
US-5591751-A CARBOSTYRIL DERIVATIVES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1997-01-07 US disclosed
EP-0684231-A1 Pharmaceutical preparation for modulating immunological reactions and new derivatives of indols and quinoline Cerbios-Pharma S.A. (CH) 1995-11-29 EP disclosed
CN-1102527-A Piperazinocarbonylcarbostyrils as peripheral vasodilators OTSUKA PHARMA CO LTD (JP) 1995-05-10 CN disclosed
EP-0636128-A1 PIPERAZINOCARBONYLCARBOSTYRILS AS PERIPHERAL VASODILATORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1995-02-01 EP disclosed
US-RE34722-E Antiulcer agents OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1994-09-06 US disclosed
WO-1994019339-A1 PIPERAZINOCARBONYLCARBOSTYRILS AS PERIPHERAL VASODILATORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1994-09-01 WO disclosed
US-4578381-A ANTIULCER AGENTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1986-03-25 US disclosed
US-4008086-A PYRIDONE OR PYRIDAZONE DERIVATIVES KONISHIROKU PHOTO INDUSTRY CO., LTD. (JA) 1977-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240374583-A1 USE OF MORPHINAN DERIVATIVES FOR TREATMENT OF OPIOID DELTA RECEPTOR AGONIST-RELATED DISEASE OPRD1, OPRM1, OPRK1 KDM4E 4829/4885ALDH1A1 1568/4885HSD17B10 2331/4885
US-12109209-B2 Use of morphinan derivatives for treatment of opioid delta receptor agonist-related disease OPRD1, OPRM1, OPRK1 KDM4E 4829/4885ALDH1A1 1568/4885HSD17B10 2331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.